Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 226, Issue SUPPL 2, Pages S282-S292Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiac216
Keywords
economics; model; lower respiratory tract illness; nirsevimab; RSV; burden; cost; infants; United States
Categories
Funding
- AstraZeneca
- Sanofi
Ask authors/readers for more resources
Universal immunization with nirsevimab for all infants could greatly reduce the health and economic burden of RSV during their first season, including a decrease in RSV-related illnesses, hospitalizations, and cost savings.
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the United States, especially among infants. Nirsevimab, an investigational long-acting monoclonal antibody, was evaluated as an immunoprophylactic strategy for infants in their first RSV season and for its potential impact on RSV-associated, medically attended lower respiratory tract illness (RSV-MALRTI) and associated costs. Methods A static decision-analytic model of the US birth cohort during its first RSV season was developed to estimate nirsevimab's impact on RSV-related health events and costs; model inputs included US-specific costs and epidemiological data. Modelled RSV-related outcomes included primary care and emergency room visits, hospitalizations including intensive care unit admission and mechanical ventilations, and RSV-related mortality. Results Under current standard of care, RSV caused 529 915 RSV-MALRTIs and 47 281 hospitalizations annually, representing $1.2 billion (2021 US dollars [USD]) in costs. Universal immunization of all infants with nirsevimab is expected to reduce 290 174 RSV-MALRTI, 24 986 hospitalizations, and expenditures of $612 million 2021 USD. Conclusions An all-infant immunization strategy with nirsevimab could substantially reduce the health and economic burden for US infants during their first RSV season. While this reduction is driven by term infants, all infants, including palivizumab-eligible and preterm infants, would benefit from this strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available